BIOFIRE® Joint Infection (JI) Panel

Be the first to leave a review
SKU
Stock
Request Info

The FDA-cleared BIOFIRE JI Panel is a comprehensive diagnostic test that identifies 39 clinically relevant targets from synovial fluid. This syndromic panel detects bacteria, yeast, and antimicrobial resistance genes, helping to reduce the time to effective therapy through rapid pathogen identification.1

Gram-Negative Bacteria

  • Bacteroides fragilis
  • Citrobacter
  • Enterobacter cloacae complex
  • Escherichia coli
  • Haemophilus influenzae
  • Kingella kingae
  • Klebsiella aerogenes
  • Klebsiella pneumoniae group
  • Morganella morganii
  • Neisseria gonorrhoeae
  • Proteus spp.
  • Pseudomonas aeruginosa
  • Salmonella spp.
  • Serratia marcescens

Yeast

  • Candida spp.
    • Candida albicans

Gram-Positive Bacteria

  • Anaerococcus prevotii/vaginalis
  • Clostridium perfringens
  • Cutibacterium avidum/granulosum
  • Enterococcus faecalis
  • Enterococcus faecium
  • Finegoldia magna
  • Parvimonas micra
  • Peptoniphilus
  • Peptostreptococcus anaerobius
  • Staphylococcus aureus
  • Staphylococcus lugdunensis
  • Streptococcus spp.
  • Streptococcus agalactiae
  • Streptococcus pneumoniae
  • Streptococcus pyogenes

Antimicrobial Resistance Genes

  • Carbapenemases
    • IMP
    • KPC
    • NDM
    • OXA-48-like
    • VIM
  • ESBL
    • CTX-M
  • Methicillin resistance
    • mecA/C and MREJ (MRSA)
  • Vancomycin Resistance
    • vanA/B

Technology: Multiplex PCR-based molecular diagnostics (syndromic approach)

Format: Single, self-contained, freeze-dried reagent pouch

Sample Type: Synovial fluid

Result Time: Approximately one hour

Ease of Use: Automated workflow from sample to result, requiring minimal hands-on time

The BioFire Joint Infection Panel is a powerful tool for the diagnosis of patients suspected of having joint infections. By providing fast and accurate results, the panel helps clinicians make more-informed decisions about antimicrobial therapy and potentially reduce the need for additional costly and time-consuming diagnostic tests.1

Related Products

  1. Esteban J, et al. Journal of Clinical Microbiology. 25 October, 2023. https://doi.org/10.1128/jcm.00357-23

Contact Us

Eager to advance your biothreat detection and infectious disease diagnostic capabilities? Connect with us to discuss how BioFire can help strengthen your preparedness and accelerate your response in critical situations.